July 23, 2020

In re Bystolic Antitrust Litigation

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. March 24, 2023

    Bystolic 'Side Deals' Deemed Legit, Not Generic Delay Plans

    Drug wholesalers, retailers and employee benefit funds made none of the complaint changes they'd need to, to undermine the legitimacy of drug supply and development deals an AbbVie predecessor struck settling patent infringement litigation staving off generic versions of hypertension drug Bystolic, according to a ruling unsealed Friday.

3 other articles on this case. View all »

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login